Grace Therapeutics, Inc. (GRCE) Live Share Price, Invest From India

Grace Therapeutics, Inc. Stock Performance

as on May 2, 2026 at 6:59 am IST

Day's Low
Day's High
$2.29
Day's Price Range
$2.49
$2.34
2.14%
Downside
6.41%
Upside
52 Week's Low
52 Week's High
$1.79
52-Week Price Range
$5.18
$2.34
23.50%
Downside
121.37%
Upside

Grace Therapeutics, Inc. share price movements today

Previous Close: $2.24
Open: $2.30
Volume: 1.1M
Day's Low - High: $2.29 - $2.49
52 Week Low - High: $1.79 - $5.18

Grace Therapeutics, Inc. Historical Returns

1 Month Return: -54.39 %
3 Month Return: -37.6 %
1 Year Return: -22.9 %
3 Year Return: 0 %
5 Year Return: 0 %

Grace Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Grace Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$34.7M

EPS (TTM)

-1.0265

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

-10.22%

Grace Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Grace Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Grace Therapeutics, Inc.	NA	$34.7M	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$41.3B	110.54%	77.57	12.55%
Vertex Pharmaceuticals Inc	BUY	$108.7B	94.28%	27.93	32.94%
BeiGene, Ltd.	NA	$32.7B	NA	118.49	5.37%
Regeneron Pharmaceuticals Inc	BUY	$74.1B	45.73%	17.27	29.65%

Stock Returns calculator for Grace Therapeutics, Inc. Stock including INR - Dollar returns

The Grace Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Grace Therapeutics, Inc. investment value today

Current value as on today

₹86,364

Returns

-₹13,636

(-13.64%)

Returns from Grace Therapeutics, Inc. Stock

-₹23,026 (-23.03%)

Dollar Impact

₹9,391 (+9.39%)

Grace Therapeutics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Grace Therapeutics, Inc. Stock has increased by 1833% in the last 30 days, reflecting an upward trend in search activity.

Time period: April 2, 2026 to May 2, 2026

Change:1833% versus previous 30 day period

Grace Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	-	-	-	-	-	0	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-2	-3	-3	-4	-4	-3	-3	-3	-2	-3
EBITDA	-3	-3	-4	-4	-4	-3	0	-3	0	-3
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	-	0
Income Before Tax	-3	-2	-4	-3	-4	-4	0	-3	0	-3
Income Tax Expense	0	0	0	0	0	0	-1	-	-	-
Net Income	-3	-2	-3	-2	-3	-4	0	-3	0	-3
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	7950.00%	0.00%	0.00%	0.00%

Grace Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Mar 2015	Mar 2016	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Revenue	0	0	0	-	-	-	-
Gross Profit	0	0	0	-	0	0	0
Operating Income	-9	-7	-16	-15	-52	-11	-16
EBITDA	-8	-2	-9	-15	-18	-14	-16
Interest Expense	0	0	0	-	-	-	-
Depreciation	-	-	0	-	0	0	0
Income Before Tax	-1	-4	-19	-10	-51	-14	-12
Income Tax Expense	-	-	-	0	-9	-1	-3
Net Income	-1	-4	-19	-9	-42	-12	-9
Net Profit Margin	-611.68%	-16777.63%	-10039.80%	0.00%	0.00%	0.00%	0.00%

Grace Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-2	-3	-2	-3	-4	0	-3	0	-2
Operating Cash Flow	-1	-2	-3	-4	-4	-2	-1	-3	-2
Investing Cash Flow	-6	6	0	0	0	-	-	-	-
Financing Cash Flow	0	0	-	-	-	14	0	0	4
Change in Cash	-8	4	-3	-4	-4	11	-2	-3	1

Grace Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Mar 2016	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Net Income	-4	-16	-39	-25	-19	-9	-42	-12	-9
Operating Cash Flow	-4	-9	-24	-22	-14	-17	-15	-12	-14
Investing Cash Flow	6	0	-9	8	-9	-3	13	0	-
Financing Cash Flow	0	8	45	13	59	-	0	7	14
Change in Cash	1	-1	10	-2	36	-20	-2	-4	0

Insights on Grace Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 3 Years
In the last 3 years, GRCE has outperformed top 5 stocks with highest market-cap in its industry
NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 15.8% return, outperforming this stock by 38.7%
NEGATIVE IMPACT
Price Dip
In the last 1 month, GRCE stock has moved down by -54.4%

About Grace Therapeutics, Inc.

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Organisation	Grace Therapeutics, Inc.
Headquarters	103 Carnegie Center, Princeton, NJ, United States, 08540
Industry	Biotechnology
CEO	Mr. Prashant Kohli
E-voting on shares	Click here to vote

Key Management of Grace Therapeutics, Inc.

Name	Title
Ms. Carrie D'Andrea	VP of Clinical Operations
Mr. Robert J. DelAversano CPA	VP of Finance and Principal Financial & Accounting Officer
Dr. R. Loch MacDonald M.D., Ph.D.	Member of Scientific Advisory Board & Chief Medical Officer
Mr. Prashant Kohli	CEO & Director
Mr. Amresh Kumar Ph.D.	VP of Program Management

FAQs

What is Grace Therapeutics, Inc. share price today?

Grace Therapeutics, Inc. share price today is $2.34 as on May 2, 2026 at 1:29 am IST at the close of the market. Grace Therapeutics, Inc. share today touched a day high of $2.49 and a low of $2.29.

What is the 52 week high and 52 week low for Grace Therapeutics, Inc. share?

Grace Therapeutics, Inc. share touched a 52 week high of $5.18 on April 2, 2026 and a 52 week low of $1.79 on April 23, 2026. Grace Therapeutics, Inc. stock price today i.e. May 2, 2026 at 1:29 am IST is closed at $2.34,which is 54.83% down from its 52 week high and 30.73% up from its 52 week low.

What is Grace Therapeutics, Inc.'s market capitalisation today?

Grace Therapeutics, Inc. market capitalisation is $0.00T as on May 2, 2026 at 1:29 am IST.

How to invest in Grace Therapeutics, Inc. Stock (GRCE) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Grace Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Grace Therapeutics, Inc. Shares that will get you 0.6410 shares as per Grace Therapeutics, Inc. share price of $2.34 per share as on May 2, 2026 at 1:29 am IST.

What is the minimum amount required to buy Grace Therapeutics, Inc. Stock (GRCE) from India?

Indian investors can start investing in Grace Therapeutics, Inc. (GRCE) shares with as little as ₹94.91 or $1 (as of May 2, 2026 at 8:38 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹949.10 in Grace Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on May 2, 2026 at 8:38 pm IST). Based on Grace Therapeutics, Inc. share’s latest price of $2.34 as on May 2, 2026 at 1:29 am IST, you will get 4.2735 shares of Grace Therapeutics, Inc.. Learn more about fractional shares .